Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Antti Rannikko is active.

Publication


Featured researches published by Antti Rannikko.


European Urology | 2013

Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study

Meelan Bul; Xiaoye Zhu; Riccardo Valdagni; Tom Pickles; Yoshiyuki Kakehi; Antti Rannikko; Anders Bjartell; Deric K. van der Schoot; Erik B. Cornel; Giario Conti; Egbert R. Boevé; Frédéric Staerman; Jenneke J. Vis-Maters; Henk Vergunst; Joris J. Jaspars; Petra Strölin; Erik van Muilekom; Fritz H. Schröder; Chris H. Bangma; Monique J. Roobol

BACKGROUNDnOverdiagnosis and subsequent overtreatment are important side effects of screening for, and early detection of, prostate cancer (PCa). Active surveillance (AS) is of growing interest as an alternative to radical treatment of low-risk PCa.nnnOBJECTIVEnTo update our experience in the largest worldwide prospective AS cohort.nnnDESIGN, SETTING, AND PARTICIPANTSnEligible patients had clinical stage T1/T2 PCa, prostate-specific antigen (PSA) ≤ 10 ng/ml, PSA density <0.2 ng/ml per milliliter, one or two positive biopsy cores, and Gleason score ≤ 6. PSA was measured every 3-6 mo, and volume-based repeat biopsies were scheduled after 1, 4, and 7 yr. Reclassification was defined as more than two positive cores or Gleason >6 at repeat biopsy. Recommendation for treatment was triggered in case of PSA doubling time <3 yr or reclassification.nnnOUTCOME MEASUREMENTS AND STATISTICAL ANALYSISnMultivariate regression analysis was used to evaluate predictors for reclassification at repeat biopsy. Active therapy-free survival (ATFS) was assessed with a Kaplan-Meier analysis, and Cox regression was used to evaluate the association of clinical characteristics with active therapy over time.nnnRESULTS AND LIMITATIONSnIn total, 2494 patients were included and followed for a median of 1.6 yr. One or more repeat biopsies were performed in 1480 men, of whom 415 men (28%) showed reclassification. Compliance with the first repeat biopsy was estimated to be 81%. During follow-up, 527 patients (21.1%) underwent active therapy. ATFS at 2 yr was 77.3%. The strongest predictors for reclassification and switching to deferred treatment were the number of positive cores (two cores compared with one core) and PSA density. The disease-specific survival rate was 100%. Follow-up was too short to draw definitive conclusions about the safety of AS.nnnCONCLUSIONSnOur short-term data support AS as a feasible strategy to reduce overtreatment. Clinical characteristics and PSA kinetics during follow-up can be used for risk stratification. Strict monitoring is even more essential in men with high-risk features to enable timely recognition of potentially aggressive disease and offer curative intervention. Limitations of using surrogate end points and markers in AS should be recognized.nnnTRIAL REGISTRATIONnThe current program is registered at the Dutch Trial Register with ID NTR1718 (http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1718).


European Urology | 2009

Outcomes of Men with Screen-Detected Prostate Cancer Eligible for Active Surveillance Who Were Managed Expectantly

Roderick C.N. van den Bergh; Stijn Roemeling; Monique J. Roobol; Gunnar Aus; Jonas Hugosson; Antti Rannikko; Teuvo L.J. Tammela; Chris H. Bangma; Fritz H. Schröder

BACKGROUNDnThe incidence of small, localised, well-differentiated prostate cancer (PCa) is increasing, mainly as a result of screening. Many of these cancers will not progress, and radical therapy may lead to substantial overtreatment. Active surveillance (AS) has emerged as an alternative.nnnOBJECTIVEnTo retrospectively validate the currently used criteria for eligibility for AS.nnnDESIGN, SETTING, AND PARTICIPANTSnFor this cohort study, data from 616 men who were diagnosed with PCa between 1994 and 2007 at a mean age of 66.3 yr in four centres of the European Randomized Study of Screening for Prostate Cancer (ERSPC) were combined. All patients fit the criteria for AS (prostate-specific antigen [PSA] < or = 10.0 ng/ml, PSA-density < 0.2 ng/ml per ml, stage T1C/T2, Gleason score < or = 3 + 3 = 6, and < or = 2 positive biopsy cores), and initially they were managed expectantly. Median follow-up was 3.91 yr.nnnMEASUREMENTSnDisease specific-, overall-, and treatment-free survival were studied. Present PSA characteristics were assessed and also compared between men who were switching to deferred active therapy during follow-up and men remaining untreated.nnnRESULTS AND LIMITATIONSnThe calculated (Kaplan-Meier) 10-yr PCa-specific survival (21 patients at risk) was 100%, which sharply contrasted with 77% overall survival. Men still alive showed favourable PSA characteristics. Although the calculated 10-yr treatment-free survival was only 43%, objective signs of progression often did not indicate the shift to radical treatment. The cohort consisted of men on AS and those on watchful waiting (WW); information on comorbidity or psychological distress was not available.nnnCONCLUSIONSnAS seems justified in selected men with screen-detected PCa. Prospective protocol-based AS programs are necessary to optimise selection criteria and to find the appropriate trigger points for switching to active therapy. Possible negative psychological reactions with AS against improved quality of life by withholding side-effects from radical treatment should be considered.


The EMBO Journal | 2011

Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer

Biswajyoti Sahu; Marko Laakso; Kristian Ovaska; Tuomas Mirtti; Johan Lundin; Antti Rannikko; Anna Sankila; Juha-Pekka Turunen; Mikael Lundin; Juho Konsti; Tiina Vesterinen; Stig Nordling; Olli Kallioniemi; Sampsa Hautaniemi; Olli A. Jänne

High androgen receptor (AR) level in primary tumour predicts increased prostate cancer‐specific mortality. However, the mechanisms that regulate AR function in prostate cancer are poorly known. We report here a new paradigm for the forkhead protein FoxA1 action in androgen signalling. Besides pioneering the AR pathway, FoxA1 depletion elicited extensive redistribution of AR‐binding sites (ARBs) on LNCaP‐1F5 cell chromatin that was commensurate with changes in androgen‐dependent gene expression signature. We identified three distinct classes of ARBs and androgen‐responsive genes: (i) independent of FoxA1, (ii) pioneered by FoxA1 and (iii) masked by FoxA1 and functional upon FoxA1 depletion. FoxA1 depletion also reprogrammed AR binding in VCaP cells, and glucocorticoid receptor binding and glucocorticoid‐dependent signalling in LNCaP‐1F5 cells. Importantly, FoxA1 protein level in primary prostate tumour had significant association to disease outcome; high FoxA1 level was associated with poor prognosis, whereas low FoxA1 level, even in the presence of high AR expression, predicted good prognosis. The role of FoxA1 in androgen signalling and prostate cancer is distinctly different from that in oestrogen signalling and breast cancer.


European Urology | 2015

Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: A Systematic Review

Ivo G. Schoots; Neophytos Petrides; Francesco Giganti; Leonard P. Bokhorst; Antti Rannikko; Laurence Klotz; Arnauld Villers; Jonas Hugosson; Caroline M. Moore

CONTEXTnThere is great interest in using magnetic resonance imaging (MRI) for men on active surveillance for prostate cancer.nnnOBJECTIVEnTo systematically review evidence regarding the use of MRI in men with low- or intermediate-risk prostate cancer suitable for active surveillance.nnnEVIDENCE ACQUISITIONnOvid Medline and Embase databases were searched for active surveillance, prostate cancer, and MRI from inception until April 25, 2014 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses process. Identified reports were critically appraised according to the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria.nnnEVIDENCE SYNTHESISnA lesion on MRI suspicious for prostate cancer (positive MRI) is seen in two-thirds of men otherwise suitable for active surveillance. A positive MRI makes the identification of clinically significant disease at repeat biopsy more likely, especially when biopsies are targeted to suspicious MRI lesions. Radical prostatectomy data show that positive MRI is more likely to be associated with upgrading (Gleason score>3+3) than a negative MRI (43% vs 27%). A positive MRI is not significantly more likely to be associated with upstaging at radical prostatectomy (>T2) than a negative MRI (10% vs 8%). Although MRI is of interest in the monitoring of men on active surveillance, robust data on the use of repeat MRI in active surveillance are lacking. Prospective studies with clear definitions of radiological significance and progression are needed before this approach can be adopted.nnnCONCLUSIONSnMRI is useful for detection of clinically significant disease at initial assessment of men considering active surveillance. To use MRI as a monitoring tool in surveillance, it will be necessary to define both radiological significance and radiological progression.nnnPATIENT SUMMARYnThis review assesses evidence for the use of magnetic resonance imaging (MRI) in men on active surveillance for prostate cancer. MRI at the start of surveillance can detect clinically significant disease in one-third to half of men. There are few data to assess the use of MRI as a monitoring tool during surveillance, so there is a need to define significant disease on MRI and significant changes over time.


BJUI | 2010

Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study

Roderick C.N. van den Bergh; Hanna Vasarainen; Henk G. van der Poel; Jenneke J. Vis-Maters; John Rietbergen; Tom Pickles; Erik B. Cornel; Riccardo Valdagni; Joris J. Jaspars; John van der Hoeven; Frédéric Staerman; Eric H. Oomens; Antti Rannikko; Stijn Roemeling; Ewout W. Steyerberg; Monique J. Roobol; Fritz H. Schröder; Chris H. Bangma

Study Type – Therapy (prospective cohort)u2028Level of Evidenceu20032b


European Urology | 2012

Radical Prostatectomy for Low-Risk Prostate Cancer Following Initial Active Surveillance: Results From a Prospective Observational Study

Meelan Bul; Xiaoye Zhu; Antti Rannikko; Frédéric Staerman; Riccardo Valdagni; Tom Pickles; Chris H. Bangma; Monique J. Roobol

BACKGROUNDnLittle is known about the outcome of radical prostatectomy (RP) in men initially followed on active surveillance (AS) for low-risk prostate cancer (PCa).nnnOBJECTIVEnEvaluate pathology findings after RP in our prospective AS cohort.nnnDESIGN, SETTING, AND PARTICIPANTSnAll men participated in the Prostate Cancer Research International: Active Surveillance (PRIAS) study. Eligible men were initially diagnosed with low-risk PCa (clinical stage ≤ T2, prostate-specific antigen [PSA] ≤ 10 ng/ml, PSA density <0.2 ng/ml per ml, one or two positive biopsy cores, and Gleason score ≤ 6) and underwent RP between December 2006 and July 2011. The study protocol recommends RP in case of risk reclassification on repeat biopsy (Gleason score >6 and/or more than two positive cores) or a PSA doubling time ≤ 3 yr.nnnMEASUREMENTSnDescriptive statistics were used to report on pathology findings for staging and grading.nnnRESULTS AND LIMITATIONSnPathology results were available in 167 out of 189 RP cases (88.4%). Median time to RP was 1.3 yr (range: 1.1-1.9). Protocol-based recommendations led to deferred RP in 143 men (75.7%); 24 men (12.7%) switched because of anxiety, and 22 (11.6%) had other reasons. Pathology results showed 134 (80.8%) organ-confined cases and 32 (19.2%) cases with extracapsular extension. Gleason scores ≤ 6, 3+4, 4+3, and 8 were found in 79 (47.3%), 64 (38.3%), 21 (12.6%), and 3 (1.8%) cases, respectively. Unfavourable RP results (pT3-4 and/or Gleason score ≥ 4+3) were found in 49 patients (29%), of whom 33 (67%) had a biopsy-related reason for deferred RP.nnnCONCLUSIONSnRP results in men initially followed on AS show organ-confined disease and favourable Gleason grading in a majority of cases. Most men in our cohort had a protocol-based reason to switch to deferred RP. A main focus for AS protocols should be to improve the selection of patients at the time of inclusion to minimise reclassification of risk and preserve the chance for curative treatment, if indicated.


BJUI | 2012

Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer

Meelan Bul; Roderick C.N. van den Bergh; Xiaoye Zhu; Antti Rannikko; Hanna Vasarainen; Chris H. Bangma; Fritz H. Schröder; Monique J. Roobol

Study Type – Therapy (outcomes)


European Urology | 2016

A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment

Leonard P. Bokhorst; Riccardo Valdagni; Antti Rannikko; Yoshiyuki Kakehi; Tom Pickles; Chris H. Bangma; Monique J. Roobol

BACKGROUNDnThe Prostate Cancer Research International Active Surveillance (PRIAS) study was initiated a decade ago to study the most optimal selection and follow-up of men on active surveillance (AS).nnnOBJECTIVEnWe report on 10 yr of follow-up of men on AS in the PRIAS study and evaluate if criteria used to recommend a switch to active treatment truly predict unfavorable outcome on subsequent radical prostatectomy (RP).nnnDESIGN, SETTING, AND PARTICIPANTSnMen with low-risk prostate cancer were included and followed prospectively on AS. Follow-up consisted of regular prostate-specific antigen (PSA) tests, digital rectal examinations, and biopsies. Men with Gleason >3+3, more than two positive biopsy cores, or stage higher than cT2 were advised to switch to active treatment (until 2014, a PSA doubling time [PSA DT] of 0-3 yr was also used).nnnOUTCOME MEASUREMENTS AND STATISTICAL ANALYSISnReclassification rates, treatment after discontinuation, and outcome on RP after discontinuing AS were reported. Regression analysis on the outcome of RP was used to evaluate the predictive value of criteria currently used to recommend a switch to active treatment. Kaplan-Meier and competing risk analysis were used to report discontinuation rates over time and long-term oncologic end points.nnnRESULTS AND LIMITATIONSnA total of 5302 men were included in PRIAS across 18 countries. Reclassification rates remained stable on all subsequent biopsies, with 22-33% of men having either Gleason >3+3 or more than two positive cores on any repeat biopsy. At 5 and 10 yr of follow-up, 52% and 73% of men, respectively, had discontinued AS, most of them because of protocol-based reclassification. A third of men undergoing subsequent RP had favorable pathologic tumor features (Gleason 3+3 and pT2). Of the criteria used to recommend a switch to active treatment, more than two positive cores and a PSA DT of 0-3 yr were not predictive of unfavorable pathologic outcome on RP.nnnCONCLUSIONSnA substantial group of men discontinued AS without subsequent unfavorable tumor features on RP; therefore, we propose Gleason upgrading and cT3 as the only indicators for an immediate switch to active treatment. Surrogate indicators (eg, more than two positive cores and a fast-rising PSA) should not trigger immediate active treatment but rather further investigation to confirm the suspicion of higher risk disease.nnnPATIENT SUMMARYnWe confirmed the safety of active surveillance as a treatment option for men with low-risk prostate cancer; however, some changes could be made to the follow-up protocol to safely increase the number of men who remain on active surveillance.


European Urology | 2012

Predictors of Unfavourable Repeat Biopsy Results in Men Participating in a Prospective Active Surveillance Program

Meelan Bul; Roderick C.N. van den Bergh; Antti Rannikko; Riccardo Valdagni; Tom Pickles; Chris H. Bangma; Monique J. Roobol

BACKGROUNDnActive surveillance (AS) protocols for low-risk prostate cancer (PCa) generally include repeat prostate biopsies at predefined follow-up intervals.nnnOBJECTIVEnTo study the outcome of routinely obtained 1-yr repeat biopsies and factors predicting reclassification to higher risk, to contribute to risk stratification for men on AS.nnnDESIGN, SETTING, AND PARTICIPANTSnWe analysed men with low-risk PCa (clinical stage ≤ T2, prostate-specific antigen (PSA) ≤ 10 ng/ml, PSA density <0.2 ng/ml per millilitre, one or two positive biopsy cores, and Gleason score ≤ 6) who had been included in a prospective AS protocol.nnnINTERVENTIONSnPSA was measured 3-monthly and the first volume-dependent repeat biopsy was scheduled 1 yr after diagnosis, independent of PSA doubling time (PSA-DT). Reclassification to higher risk disease on repeat biopsy was defined as Gleason score ≥ 7 or ≥ 3 positive cores.nnnMEASUREMENTSnWe analysed whether baseline patient characteristics and PSA-DT were associated with reclassification to more aggressive PCa on repeat biopsy.nnnRESULTS AND LIMITATIONSnA first repeat biopsy was taken in 757 patients after median follow-up of 1.03 yr. The results of repeat biopsies were favourable (no or low-risk PCa) in 594 patients (78.5%) and led to reclassification of risk in 163 (21.5%). Analysis showed that reclassification to higher risk was significantly influenced by the number of initial positive cores (two vs one) (odds ratio [OR]: 1.8; p=0.002) and higher PSA density (OR: 2.1; p=0.003). The outcome was not significantly influenced by age, clinical stage, total number of biopsy cores, or PSA. Adding PSA-DT at time of repeat biopsy to the model showed PSA-DT <3 yr to be significantly associated with reclassification to higher risk (OR: 1.7; p=0.015). Data on tumour involvement per biopsy core were not available.nnnCONCLUSIONSnClinical features at baseline and during follow-up in our AS cohort are significantly associated with short-term reclassification to higher risk on repeat biopsy. These characteristics can potentially be used for risk stratification of men with PCa who are apparently at favourable risk.


Oncogene | 2012

Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion

Mari Björkman; Päivi Östling; Ville Härmä; Johannes Virtanen; J-P Mpindi; Juha Rantala; Tuomas Mirtti; Tiina Vesterinen; Mikael Lundin; Anna Sankila; Antti Rannikko; E Kaivanto; Pekka Kohonen; Olli Kallioniemi

Our understanding of key epigenetic regulators involved in specific biological processes and cancers is still incomplete, despite great progress in genome-wide studies of the epigenome. Here, we carried out a systematic, genome-wide analysis of the functional significance of 615 epigenetic proteins in prostate cancer (PrCa) cells. We used the high-content cell-spot microarray technology and siRNA silencing of PrCa cell lines for functional screening of cell proliferation, survival, androgen receptor (AR) expression, histone methylation and acetylation. Our study highlights subsets of epigenetic enzymes influencing different cancer cell phenotypes. Plant homeo domain (PHD) finger proteins have a key role in cell survival and histone methylation, whereas histone deacetylases were primarily involved in regulating AR expression. In contrast, JumonjiC-domain (JmjC) containing histone lysine demethylases (KDMs) mainly had an impact on cell proliferation. Our results show that the KDMs JARID1B, PHF8, KDM3A, KDM3B and KDM4A were highly expressed in clinical PrCa samples. The PHD-finger protein 8 (PHF8), a transcriptional coactivator with both PHD- and JmjC-domains, was moderately to strongly expressed in 80% of clinical PrCa samples, whereas 76% of normal and benign samples were negative or only showed weak PHF8 expression. Strong PHF8 expression correlated significantly with high Gleason grade and was borderline significant for poor prognosis. The results of functional PHF8 knockdown implicate a role in cell migration and invasion, as shown by cell motility and 3-D invasion assays. Our study suggests that various cellular phenotypes are regulated by distinct subsets of epigenetic enzymes. Proteins interpreting and modifying histone methylation, such as JmjC-domain and particularly PHD-finger proteins like PHF8, are activated in subsets of PrCas and promote cancer relevant phenotypes.

Collaboration


Dive into the Antti Rannikko's collaboration.

Top Co-Authors

Avatar

Monique J. Roobol

Erasmus University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Chris H. Bangma

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hanna Vasarainen

Helsinki University Central Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tom Pickles

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Kimmo Taari

Helsinki University Central Hospital

View shared research outputs
Top Co-Authors

Avatar

Fritz H. Schröder

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anssi Petas

Helsinki University Central Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge